Dicoumarol as an IRE1α Inhibitor in ER Stress-Induced Liver Injury: Insights from Molecular Docking and Functional Screening

Study Background and Research Question

Drug-induced liver injury is a critical clinical challenge, with endoplasmic reticulum (ER) dysfunction playing a central role in pathogenesis. The ER is responsible for protein folding, modification, and trafficking in hepatocytes—processes highly sensitive to stressors such as toxins or metabolic overload. When protein misfolding overwhelms the ER's quality control systems, the unfolded protein response (UPR) is triggered to restore homeostasis or induce cell death if the stress is unresolved. Among the UPR transducers, the IRE1α/XBP1 axis is highly conserved and pivotal in regulating adaptive and apoptotic responses. The present study sought to identify natural compounds that modulate IRE1α activity to alleviate ER stress and associated liver injury (paper).

Key Innovation from the Reference Study

The primary innovation lies in combining molecular docking with a functional, cell-based reporter assay to screen ATP-competitive molecules targeting the kinase domain of IRE1α. This dual approach enhances the specificity and biological relevance of candidate selection. Dicoumarol (DIC) emerged as a top hit, demonstrating selective inhibition of IRE1α activation and downstream signaling in multiple hepatic cell models. Notably, this is among the first reports to validate dicoumarol as a pharmacological inhibitor of IRE1α with protective effects in an in vivo model of acute ER stress-induced liver injury (paper).

Methods and Experimental Design Insights

The study adopted a multi-tiered screening platform:

• Virtual Screening: Molecular docking identified ATP-competitive small molecules predicted to bind the IRE1α kinase domain.
• Reporter-Based Functional Assay: Candidate compounds were tested using XBP1s-reporter cell lines (HEK293T, HepG2, and primary hepatocytes). Flow cytometry quantified mean fluorescence intensity (MFI) reflecting XBP1s-driven transcriptional activity as a readout of IRE1α signaling.
• In Vitro Validation: The top compound (dicoumarol) was characterized for its impact on IRE1α pathway activation after ER stress induction (using tunicamycin or thapsigargin) in vitro.
• In Vivo Efficacy: Mice were subjected to acute hepatic ER stress via carbon tetrachloride (CCl₄) or tunicamycin, followed by dicoumarol administration to assess liver protection.

Assay readouts included XBP1 splicing, ER stress markers, liver histology (H&E staining), and markers of apoptosis and inflammation.

Protocol Parameters

• ER stress induction (tunicamycin) | 2 μg/mL (in vitro), 1 mg/kg (in vivo) | Cell and animal models | Robustly triggers UPR/ER stress for functional screening | paper
• ER stress induction (thapsigargin) | 1 μM | Cell culture | SERCA inhibition as an alternative ER stressor; enables cross-validation of UPR activation | paper; product_spec
• Dicoumarol dosing | 10–50 μM (in vitro), 10 mg/kg (in vivo) | Dose range for screening and efficacy | Provides concentration-dependent inhibition of IRE1α with measurable cellular and histological outcomes | paper
• XBP1s-reporter readout | MFI via flow cytometry | Quantifies IRE1α pathway activation | Allows rapid, quantitative assessment of candidate inhibitor efficacy | paper
• Thapsigargin alternative dosing | 50–100 nM | Calcium signaling/apoptosis assays | For reproducible ER calcium depletion and stress induction in mechanistic studies | workflow_recommendation

Core Findings and Why They Matter

Dicoumarol selectively inhibited IRE1α activation in both immortalized (HEK293T, HepG2) and primary hepatocytes, as evidenced by reduced XBP1 splicing and lower MFI in reporter assays. Upon challenge with tunicamycin or carbon tetrachloride, dicoumarol administration led to substantial amelioration of liver injury in mice, including improved histology, decreased apoptosis, and lower expression of inflammatory mediators (paper).

These findings position dicoumarol as a tool compound for dissecting IRE1α-driven ER stress responses and as a candidate for therapeutic development in liver injury models where ER stress is central. The robust screening platform established in this study can serve as a model for future discovery of UPR modulators.

Comparison with Existing Internal Articles

While the current study centers on IRE1α inhibition and ER stress in liver injury, several internal resources provide complementary insights into the broader landscape of ER stress modulation and calcium signaling:

• Thapsigargin as a Precision SERCA Inhibitor: Internal articles such as "Thapsigargin: Gold-Standard SERCA Inhibitor for Calcium Sign..." and "Thapsigargin: Precision SERCA Inhibition for Calcium Sign..." emphasize thapsigargin’s utility in apoptosis assays, ER stress research, and calcium signaling pathway studies. Thapsigargin induces ER stress through disruption of Ca²⁺ homeostasis, offering a complementary approach to chemical genetic modulation of the UPR.
• Dicoumarol and IRE1α: The internal summary at dilutionbuffer.com specifically discusses the current paper’s identification of dicoumarol as a pharmacological IRE1α inhibitor, reinforcing the importance of this axis in liver pathophysiology.

Researchers can leverage both thapsigargin and dicoumarol to dissect distinct yet interconnected pathways—calcium-dependent and IRE1α-mediated arms—within ER stress biology.

Limitations and Transferability

Model Specificity: The study’s findings are robust in the context of acute ER stress-induced liver injury in mice. However, translation to chronic disease models or other organ systems requires further validation. Dicoumarol’s selectivity and off-target effects, particularly in non-hepatic tissues, remain to be fully characterized.

Assay Transferability: While the XBP1s-reporter platform is broadly adaptable, the functional consequences of IRE1α inhibition may differ depending on cell type, stressor, and experimental context. Similarly, the use of thapsigargin as an ER stressor is well-established but requires careful titration to avoid non-specific cytotoxicity (workflow_recommendation).

Research Support Resources

For researchers aiming to model ER stress, apoptosis, or calcium signaling pathways, standardized reagents are essential. Thapsigargin (SKU B6614) from APExBIO offers nanomolar potency and reproducibility as a SERCA pump inhibitor, enabling precise induction of ER stress and calcium homeostasis disruption in vitro and in vivo (source: product_spec). When used alongside platforms like XBP1s-reporter assays or in combination with pharmacological IRE1α inhibitors such as dicoumarol, thapsigargin supports multifaceted interrogation of ER stress mechanisms in liver and related disease models. Always refer to validated protocols and titrate concentrations to your specific experimental system.